In Silico Testing of Some Protected Galactopyranose as SARS-CoV-2 Main Protease Inhibitors
Abstract
An outbreak of novel Coronavirus disease (COVID-19 or 2019-nCoV) due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has already demonstrated a fatal death toll all over the world. To cure this viral infection, a number of compounds of different categories have been investigated in silico. Some of the compounds showed better binding energy with COVID-19-related proteins. However, until now there is no appropriate drug except a vaccine. It was found that many antifungal drugs are used for COVID-19 patients in hospitals. Many monosaccharide esters have been reported to have antifungal potential. Thus, in the present study, some protected galactopyranose esters are chosen for molecular docking with SARS-CoV-2 main proteases (PDB id: 7BQY and 6LU7). A docking study revealed that galactopyranose esters 5-8 have very good docking scores (-8.4 to -6.5 kcal/mol) compared to the standard drugs azithromycin, remdesivir, and hydroxychloroquine. To explain such good scores interaction between amino acid residues of proteins and compounds in their docked complexes are calculated and duly discussed in this study.
References
Peng, Z., Xing-Lou, Y., Xian-Guang, W., Ben, H., Lei, Z., & Wei, Z. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7.
Dhumad, A.M., Majeed, H.J., Harismah, K., & Zandi, H. (2021). In silico Approach on ribavirin inhibitors for COVID-19 main protease. Bioint. Res. Appl. Chem., 11(6), 13924–13933. https://doi.org/10.33263/BRIAC116.1392413933
Rout, J., Swain, B.C., & Tripathy, U. (2022) In silico investigation of spice molecules as potent inhibitor of SARS-CoV-2, Journal of Biomolecular Structure and Dynamics, 40(2), 860–874, https://doi.org/10.1080/07391102.2020.1819879
Rashdan, H.R.M, Abdelmonsef, A.H., Abou-Krisha, M.M., & Yousef, T.A. (2022). Synthesis and identification of novel potential thiadiazole based molecules containing 1,2,3-triazole moiety against COVID-19 main protease through structure-guided virtual screening approach. Bioint. Res. Appl. Chem., 12(6), 8258–8270. https://doi.org/10.33263/BRIAC126.82588270
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel Coronavirus from patients with pneumonia in China, 2019. New Engl. J. Med., 382, 727–733. https://doi.org/10.1056/NEJMoa2001017
Prescott, H.C. (2021). Outcomes for patients following hospitalization for COVID-19. JAMA. 325(15), 1511–1512. https://doi.org/10.1001/jama.2021.3430
Kordzadeh, A., & Saadatabadi, A.R. (2022). Effects of the temperature and the pH on the main protease of SARS-CoV-2: A molecular dynamics simulation study. Bioint. Res. Appl. Chem., 12(6), 7239–7248. https://doi.org/10.33263/BRIAC126.72397248
Zhang, L., Hou, J., Ma, F.Z. et al. (2021). The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch. Virol., 166, 2071–2087. https://doi.org/10.1007/s00705-021-05012-2
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., et al. (2020).COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395, 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. (2020). Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.03.17.20037432
Md Nayeem, S., Sohail, E. M., Srihari, N. V., Indira, P., & Srinivasa Reddy, M. (2021). Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. Journal of Biomolecular Structure and Dynamics, 1-8. https://doi.org/10.1080/07391102.2021.1924262
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol., 19, 141–154. https://doi.org/10.1038/s41579-020-00459-7
Shah, A.S., Gribben, C., Bishop, J., Hanlon, P., Caldwell, D., Wood, R., Reid, M., McMenamin, J., Goldberg, D., Stockton, D., et al. (2021). Effect of vaccination on transmission of SARS-CoV-2. New Engl. J. Med., 385, 1718–1720. https://doi.org/10.1056/NEJMc2106757
Tarighi, P., Eftekhari, S., Chizari, M., Sabernavaei, M., Jafari, D., & Mirzabeigi, P. (2021). A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur. J. Pharmacol., 895, 173890. https://doi.org/10.1016/j.ejphar.2021.173890
Ghosh, R., Chakraborty, A., Biswas, A., & Chowdhuri, S. (2021). Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors – An in silico docking and molecular dynamics simulation study. Journal of Biomolecular Structure & Dynamics, 39, 4362–4374. https://doi.org/10.1080/07391102.2020.1779818
Fischer, W., Eron, J.J., Holman, W., Cohen, M.S., Fang, L., Szewczyk, L.J., Sheahan, T.P., Baric, R., Mollan, K.R., Wolfe, C.R., et al. (2021). Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv, https://doi.org/10.1101/2021.06.17.21258639
Rothan, H.A., Stone, S., Natekar, J., Kumari, P., Arora, K., & Kumar, M. (2020). The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology, 547, 7–11. https://doi.org/10.1016/j.virol.2020.05.002
Cirri, D., Marzo, T., Tolbatov, I., Marrone, A., Saladini, F., Vicenti, I., Dragoni, F., Boccuto, A., & Messori, L. (2021). In vitro anti-SARS-CoV-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study. Biomolecules, 11, 1858. https://doi.org/10.3390/biom11121858
Lee, Y.-K., Chang, W.-C., Prakash, E., Peng, Y.-J., Tu, Z.-J., Lin, C.-H., Hsu, P.-H., & Chang, C.-F. (2022). Carbohydrate Ligands for COVID-19 spike proteins. Viruses, 14, 330. https://doi.org/10.3390/v14020330
Kasthuri, M., Li, C., Verma, K., Russell, O.O., Dickson, L., McCormick, L., Bassit, L., Amblard, F., & Schinazi, R.F. (2020). Synthesis of 4'-substituted-2'-deoxy-2'-alpha-fluoro nucleoside analogs as potential antiviral agents. Molecules, 25, 1258. https://doi.org/10.3390/molecules25061258
Sari, O., Bassit, L., Gavegnano, C., McBrayer, T.R., McCormick, L., Cox, B., Coats, S.J., Amblard, F., & Schinazi, R.F. (2017). Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs. Tetrahedron Lett., 58, 642–644. https://doi.org/10.1016/j.tetlet.2017.01.006
Schultz, D.C., Johnson, R.M., Ayyanathan, K. et al. (2022). Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature, 604, 134–140. https://doi.org/10.1038/s41586-022-04482-x
Zenchenko, A.A., Drenichev, M.S., Il’icheva, I.A., & Mikhailov, S.N. (2021). Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action. Molecular Biology, 55, 786–812. https://doi.org/10.1134/S0026893321040105
Kabir, A.K.M.S., Matin, M.M., Mridha, M.A.U., & Shahed, S.M. (1998). Antifungal activities of some methyl 6-O-trityl-α-D-mannopyranosides, The Chittagong University Journal of Science, 22(1), 41–46. ISSN: 1561-1167
Matin, M.M., & Ibrahim, M. (2010). Synthesis of some methyl 4-O-octanoyl-α-L-rhamnopyranoside derivatives. Journal of Applied Sciences Research, 6(10), 1527–1532. ISSN: 1816-157X
Matin, M.M., & Chakraborty, P. (2020). Synthesis, spectral and DFT characterization, PASS predication, antimicrobial, and ADMET studies of some novel mannopyranoside esters. Journal of Applied Science & Process Engineering, 7(2), 572–586. e-ISSN: 2289-7771
Matin, M.M., Bhuiyan, M.M.H., Hossain, M.M., & Roshid M.H.O. (2015). Synthesis and comparative antibacterial studies of some benzylidene monosaccharide benzoates. Journal of the Turkish Chemical Society Section A: Chemistry, 2(4), 12–21. e-ISSN: 2149-0120
Rahman, M.A., Chakma, U., Kumer, A., Rahman, M.R., & Matin, M.M. (2023). Uridine-derived 4-aminophenyl 1-thioglucosides: DFT optimized FMO, ADME, and antiviral activities study. Biointerface Research in Applied Chemistry, 13(1), 52.https://doi.org/10.33263/BRIAC131.052
Kabir, A.K.M.S., Matin, M.M., & Kawsar, S.M.A. (1998). Synthesis and antibacterial activities of some uridine derivatives. The Chittagong University Journal of Science, 22(1), 13–18. ISSN: 1561-1167
Kabir, A.K.M.S., Matin, M.M., Sanaullah, A.F.M., Sattar, M.A., & Rahman, M.S. (2001). Antimicrobial activities of some lyxoside derivatives. Bangladesh Journal of Microbiology, 18(1), 89–95. ISSN: 1011-9981
Kabir, A.K.M.S., Matin, M.M., Bhuiyan, M.M.R., Rahim, M.A., & Rahman, M.S. (2005). Biological evaluation of some monosaccharide derivatives. International Journal of Agriculture & Biology, 7(2), 218-221. ISSN: 1814-9596
Hanee, U., Rahman, M.R., & Matin, M.M. (2021). Synthesis, PASS, in silico ADMET, and thermodynamic studies of some galactopyranoside esters. Physical Chemistry Research, 9(4), 591-603.
https://doi.org/10.22036/pcr.2021.282956.1911
Siddikey, F., Roni, M.A.H., Kumer, A., Chakma, U., & Matin, M.M. (2022). Computational investigation of Betalain derivatives as natural inhibitor against food borne bacteria. Current Chemistry Letters, 11(3), 309–320. http://dx.doi.org/10.5267/j.ccl.2022.3.003
Rahman, M.A., Matin, M.M., Kumer, A., Chakma, U., & Rahman, M.R. (2022). Modified D-Glucofuranoses as New Black Fungus Protease Inhibitors: Computational Screening, Docking, Dynamics, and QSAR Study. Physical Chemistry Research, 10(2), 195–209. https://doi.org/10.22036/pcr.2021.294078.1934
Kumer, A., Chakma, U., & Matin, M.M. (2022). Bilastine based drugs as SARS-CoV-2 protease inhibitors: Molecular docking, dynamics, and ADMET related studies. Orbital: The Electronic Journal of Chemistry, 14(1), 15–23. http://dx.doi.org/10.17807/orbital.v14i1.1642
Zago, E., Joly, N., Chaveriat, L., Vincent Lequart, V., & Martin, P., (2021). Enzymatic synthesis of amphiphilic carbohydrate esters: Influence of physicochemical and biochemical parameters, Biotechnology Reports, 30, e00631, https://doi.org/10.1016/j.btre.2021.e00631
Kim, H. J., Kang, S. H., Choi, S. S., & Kim, E. S. (2017). Redesign of antifungal polyene glycosylation: engineered biosynthesis of disaccharide-modified NPP. Applied Microbiology & Biotechnology, 101, 5131–5137. https://doi.org/10.1007/s00253-017-8303-8
Kabir, A.K.M.S., & Matin, M.M. (1994). Regioselective acylation of a derivative of L-rhamnose using the dibutyltin oxide method. Journal of the Bangladesh Chemical Society, 7(1), 73–79. ISSN: 1022-016X
Matin, M.M. (2008). Synthesis of D-glucose derived oxetane: 1,2-O-isopropylidene-4-(S)-3-O,4-C-methylene-5-O-methanesulfonyl-β-L-threo-pento-1,4-furanose. Journal of Applied Sciences Research, 4(11), 1478–1482. ISSN: 1816-157X
Kabir, A.K.M.S., Matin, M.M., Hossain, A., & Sattar, M.A. (2003). Synthesis and antimicrobial activities of some rhamno-pyranoside derivatives. Journal of the Bangladesh Chemical Society, 16(2), 85–93. ISSN: 1022-016X
Matin, M.M. (2006). Synthesis of some silyl protected 1,4-galactonolactone derivatives. Journal of Applied Sciences Research, 2(10), 753–756. ISSN: 1816-157X
Kumbhar, P.S., Pandya, A.K., Manjappa, A.S., Disouza, J.I., & Patravale, V.B. (2021). Carbohydrates-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19. Carbohydrate Polymer Technologies and Applications, 2, 100052. https://doi.org/10.1016/j.carpta.2021.100052
Islam, N, Islam, M.D., Rahman, M.R., & Matin, M.M. (2021). Octyl 6-O-hexanoyl-β-D-glucopyranosides: Synthesis, PASS, antibacterial, in silico ADMET, and DFT studies. Current Chemistry Letters, 10(4), 413–426. http://dx.doi.org/10.5267/j.ccl.2021.5.003
Matin, M.M., Uzzaman, M., Chowdhury, S.A., & Bhuiyan, M.M.H. (2022). In vitro antimicrobial, physicochemical, pharmacokinetics, and molecular docking studies of benzoyl uridine esters against SARS-CoV-2 main protease. Journal of Biomolecular Structure and Dynamics, 40(8), 3668-3680. https://doi.org/10.1080/07391102.2020.1850358
Matin, P., Matin, M.M., Rahman, M.R., & Kumer, A. (2023). Synthesis, antifungal, and molecular docking studies of some new di-O-isopentanoyl glucopyranosides. Physical Chemistry Research, 11(1), 149–157. https://doi.org/10.22036/PCR.2022.334577.2057
Kumer, A., Chakma, U., Matin, M.M., Akash, S., Chando, A., & Howlader, D. (2021). The computational screening of inhibitor for black fungus and white fungus by D-glucofuranose derivatives using in silico and SAR study. Organic Communications, 14(4), 305–322. https://doi.org/10.25135/agc.oc.116.2108.2188
Matin, M. M., Bhuiyan, M. M. H., Debnath, D. C., & Manchur, M. A. (2013). Synthesis and comparative antimicrobial studies of some acylated D-glucofuranose and D-glucopyranose derivatives. International Journal of Biosciences, 3(8), 279–287. http://dx.doi.org/10.12692/ijb/3.8.279-287
Matin, P., Rahman, M.R., Huda, D., Bakri, M.K.B., Uddin, J., Yurkin, Y., Burko, A., Kuok, K.K., & Matin, M.M. (2022). Application of synthetic acyl glucopyranosides for white-rot and brown-rot fungal decay resistance in aspen and pine wood. BioResources, 17(2), 3025–3041. https://doi.org/10.15376/biores.17.2.3025-3041
James, A.A., Rahman, M.R., Huda, D., Aqlan, M.F.M., Matin, M.M., Bakri, M.K.B., Kuok, K.K., Rahman, M.M. (2022). Synthesis and characterization of novel nano-carbon mixture from Dabai (Canarium odontophyllum) nutshell. BioResources, 17(3), 4452–4469. https://doi.org/10.15376/biores.17.3.4452-4469
Khui, P.L.N., Rahman, M.R., Matin, M.M., & Bakri, M.K.B. (2022). Recycled Rubber Waste Plastic and its Composites. In: Recycled Plastic Biocomposites, Rahman, M.R. & Bakri, M.K.B. (Eds), 1st Ed, Woodhead Publishing/Elsevierpp 147–163. https://doi.org/10.1016/B978-0-323-88653-6.00014-6
Matin, P., Hanee, U., Alam, M.S., Jeong, J.E., Matin, M.M., Rahman, M.R., Mahmud, S., Alshahrani, M.M., & Kim, B. (2022). Novel galactopyranoside esters: Synthesis, mechanism, in vitro antimicrobial evaluation and molecular docking studies. Molecules, 27(13), 4125. https://doi.org/10.3390/molecules27134125
Matin, M.M., & Azad, A.K.M.S. (2006). Synthesis of some protected 6-O-acyl-galactopyranose derivatives. Journal of Applied Sciences Research, 2(12), 1199–1202. ISSN: 1816-157X
Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., et al. (2013). Gaussian 09W, Revision D.01. Gaussian, Inc., Wallingford CT.
Lu, L., Hu, H., Hou, H., & Wang, B. (2013). An improved B3LYP method in the calculation of organic thermochemistry and reactivity. Computational and Theoretical Chemistry, 1015, 64-71. https://doi.org/10.1016/j.comptc.2013.04.009.
Veronika Temml, Zsofia Kutil, Z. (2021). Structure-based molecular modeling in SAR analysis and lead optimization. Computational and Structural Biotechnology Journal, 19, 1431-1444. https://doi.org/10.1016/j.csbj.2021.02.018.
Matin, M. M., Ibrahim, M., Anisa, T. R., & Rahman, M. R. (2022). Synthesis, characterization, in silico optimization, and conformational studies of methyl 4-O-palmitoyl-α-L-rhamnopyranosides. Malaysian Journal of Science, 41(1), 91-105. https://doi.org/10.22452/mjs.vol41no1.6
Torneri, A., Libin, P., Vanderlocht, J., Vandamme, A.-M., Neyts, J., & Hens, N. (2020). A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. BMC Medicine, 18(191). https://doi.org/10.1186/s12916-020-01636-4
Matin, M. M., Bhuiyan, M. M. H., Kibria, S. M., & Hasan, M. S. (2022). Synthesis, PASS predication of antimicrobial activity and pharmacokinetic properties of hexanoyl galactopyranosides and experimental evaluation of their action against four human pathogenic bacteria and four fungal strains. Pharmaceutical Chemistry Journal, 56(5), 627-637. https://doi.org/10.1007/s11094-022-02687-y
Ristovski, J.T., Matin, M.M., Kong, R., Kusturica, M.P., Zhang, H. (2022). In vitro testing and computational analysis of specific phytochemicals with antiviral activities considering their possible applications against COVID-19. South African Journal of Botany, 1–11. https://doi.org/10.1016/j.sajb.2022.02.009
Narayanan, A., Narwal, M., Majowicz, S.A. et al. (2022). Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Communications Biology, 5, 169. https://doi.org/10.1038/s42003-022-03090-9
Niknam, Z., Jafari, A., Golchin, A., Pouya, F.D., Nemati, M., Rezaei-Tavirani, M., & Rasmi, Y. 2022). Potential therapeutic options for COVID-19: an update on current evidence. Eur. J. Med. Res., Vol.27, No.6. https://doi.org/10.1186/s40001-021-00626-3
Mirtaleb, M.S., Mirtaleb, A.H., Nosrati, H., Heshmatnia, J., Falak, R., & Emameh, R.M. (2021). Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy, Biomedicine & Pharmacotherapy, 138, 111518. https://doi.org/10.1016/j.biopha.2021.111518
Copyright (c) 2022 UNIMAS Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Transfer Statement for Journal
1) In signing this statement, the author(s) grant UNIMAS Publisher an exclusive license to publish their original research papers. The author(s) also grant UNIMAS Publisher permission to reproduce, recreate, translate, extract or summarize, and to distribute and display in any forms, formats, and media. The author(s) can reuse their papers in their future printed work without first requiring permission from UNIMAS Publisher, provided that the author(s) acknowledge and reference publication in the Journal.
2) For open access articles, the author(s) agree that their articles published under UNIMAS Publisher are distributed under the terms of the CC-BY-NC-SA (Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work of the author(s) is properly cited.
3) For subscription articles, the author(s) agree that UNIMAS Publisher holds copyright, or an exclusive license to publish. Readers or users may view, download, print, and copy the content, for academic purposes, subject to the following conditions of use: (a) any reuse of materials is subject to permission from UNIMAS Publisher; (b) archived materials may only be used for academic research; (c) archived materials may not be used for commercial purposes, which include but not limited to monetary compensation by means of sale, resale, license, transfer of copyright, loan, etc.; and (d) archived materials may not be re-published in any part, either in print or online.
4) The author(s) is/are responsible to ensure his or her or their submitted work is original and does not infringe any existing copyright, trademark, patent, statutory right, or propriety right of others. Corresponding author(s) has (have) obtained permission from all co-authors prior to submission to the journal. Upon submission of the manuscript, the author(s) agree that no similar work has been or will be submitted or published elsewhere in any language. If submitted manuscript includes materials from others, the authors have obtained the permission from the copyright owners.
5) In signing this statement, the author(s) declare(s) that the researches in which they have conducted are in compliance with the current laws of the respective country and UNIMAS Journal Publication Ethics Policy. Any experimentation or research involving human or the use of animal samples must obtain approval from Human or Animal Ethics Committee in their respective institutions. The author(s) agree and understand that UNIMAS Publisher is not responsible for any compensational claims or failure caused by the author(s) in fulfilling the above-mentioned requirements. The author(s) must accept the responsibility for releasing their materials upon request by Chief Editor or UNIMAS Publisher.
6) The author(s) should have participated sufficiently in the work and ensured the appropriateness of the content of the article. The author(s) should also agree that he or she has no commercial attachments (e.g. patent or license arrangement, equity interest, consultancies, etc.) that might pose any conflict of interest with the submitted manuscript. The author(s) also agree to make any relevant materials and data available upon request by the editor or UNIMAS Publisher.
To download Copyright Transfer Statement for Journal, click here
